Literature DB >> 25871955

Cortisol dysregulation in obesity-related metabolic disorders.

Rene Baudrand1, Anand Vaidya.   

Abstract

PURPOSE OF REVIEW: The present review highlights recent investigations in the prior 18 months focusing on the role of dysregulated cortisol physiology in obesity as a potential modifiable mechanism in the pathogenesis of obesity-related cardiometabolic disorders. RECENT
FINDINGS: Given the clinical resemblance of obesity-related metabolic disorders with the Cushing's syndrome, new studies have investigated the intracellular regulation and metabolism of cortisol, new measurements of cortisol in scalp hair as a tool for long-term exposure to cortisol, and the cortisol-mineralocorticoid receptor pathway. Thus, current and future pharmacological interventions in obesity may include specific inhibition of steroidogenic and regulatory enzymes as well as antagonists of the mineralocorticoid and glucocorticoid receptors.
SUMMARY: The understanding of how adrenal function is challenged by the interplay of our genetic and environmental milieu has highlighted the importance of inappropriate cortisol regulation in cardiometabolic disorders. Increased adipose tissue in obesity is associated with hypothalamic-pituitary-adrenal axis overactivation, increased cortisol production at the local tissue level, and probably higher mineralocorticoid receptor activation in certain tissues.

Entities:  

Mesh:

Year:  2015        PMID: 25871955      PMCID: PMC4517681          DOI: 10.1097/MED.0000000000000152

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  72 in total

1.  Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice.

Authors:  Nicholas M Morton; Janice M Paterson; Hiroaki Masuzaki; Megan C Holmes; Bart Staels; Catherine Fievet; Brian R Walker; Jeffrey S Flier; John J Mullins; Jonathan R Seckl
Journal:  Diabetes       Date:  2004-04       Impact factor: 9.461

2.  Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension.

Authors:  Sukrut Shah; Anne Hermanowski-Vosatka; Kendra Gibson; Rae Ann Ruck; Gang Jia; John Zhang; Peggy M T Hwang; Nicholas W Ryan; Ronald B Langdon; Peter U Feig
Journal:  J Am Soc Hypertens       Date:  2011-03-21

3.  Hepatic 11β-hydroxysteroid dehydrogenase type 1 activity in obesity and type 2 diabetes using a novel triple tracer cortisol technique.

Authors:  Simmi Dube; Barbara Norby; Vishwanath Pattan; Ravi K Lingineni; Ravinder J Singh; Rickey E Carter; Ananda Basu; Rita Basu
Journal:  Diabetologia       Date:  2014-04-26       Impact factor: 10.122

Review 4.  11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  J Clin Endocrinol Metab       Date:  2009-10-16       Impact factor: 5.958

5.  Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.

Authors:  René Baudrand; Cristian A Carvajal; Arnoldo Riquelme; Mauricio Morales; Nancy Solis; Margarita Pizarro; Alex Escalona; Camilo Boza; Gustavo Pérez; Angélica Domínguez; Marco Arrese; Carlos E Fardella
Journal:  Obes Surg       Date:  2009-08-19       Impact factor: 4.129

6.  LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

Authors:  Xavier Bertagna; Rosario Pivonello; Maria Fleseriu; Yiming Zhang; Paul Robinson; Ann Taylor; Catherine E Watson; Mario Maldonado; Amir H Hamrahian; Marco Boscaro; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

7.  Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.

Authors:  L Alberti; A Girola; L Gilardini; A Conti; S Cattaldo; G Micheletto; C Invitti
Journal:  Int J Obes (Lond)       Date:  2007-06-26       Impact factor: 5.095

8.  Abnormal aldosterone physiology and cardiometabolic risk factors.

Authors:  Anand Vaidya; Patricia C Underwood; Paul N Hopkins; Xavier Jeunemaitre; Claudio Ferri; Gordon H Williams; Gail K Adler
Journal:  Hypertension       Date:  2013-02-11       Impact factor: 10.190

9.  Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements.

Authors:  Paal Methlie; Simon Dankel; Tone Myhra; Bjørn Christensen; Jennifer Gjerde; Dag Fadnes; Villy Våge; Kristian Løvås; Gunnar Mellgren
Journal:  Obesity (Silver Spring)       Date:  2013-06-13       Impact factor: 5.002

10.  Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver.

Authors:  D P Macfarlane; P J Raubenheimer; T Preston; C D Gray; M E Bastin; I Marshall; J P Iredale; R Andrew; B R Walker
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2014-08-07       Impact factor: 4.052

View more
  15 in total

1.  Cortisol, oxytocin, and quality of life in major depressive disorder.

Authors:  Ai Ling Tang; Susan J Thomas; Theresa Larkin
Journal:  Qual Life Res       Date:  2019-06-21       Impact factor: 4.147

2.  Knowing it When You See it: The Need for Continuing Innovation in Research on Healthcare Discrimination.

Authors:  Kim Rhoads; Daniel Dohan
Journal:  J Gen Intern Med       Date:  2015-10       Impact factor: 5.128

Review 3.  The Expanding Spectrum of Primary Aldosteronism: Implications for Diagnosis, Pathogenesis, and Treatment.

Authors:  Anand Vaidya; Paolo Mulatero; Rene Baudrand; Gail K Adler
Journal:  Endocr Rev       Date:  2018-12-01       Impact factor: 19.871

4.  Evening chronotype is associated with severe NAFLD in obesity.

Authors:  Claudia Vetrani; Luigi Barrea; Ludovica Verde; Gerardo Sarno; Annamaria Docimo; Giulia de Alteriis; Silvia Savastano; Annamaria Colao; Giovanna Muscogiuri
Journal:  Int J Obes (Lond)       Date:  2022-06-08       Impact factor: 5.551

5.  Hypothalamic-pituitary-adrenal axis, subjective, and thermal stress responses in midlife women with vasomotor symptoms.

Authors:  Margo D Nathan; Aleta Wiley; Pamela B Mahon; Julie Camuso; Kathryn Sullivan; Kathleen McCormick; Akanksha Srivastava; Kim Albert; Paul Newhouse; Hadine Joffe
Journal:  Menopause       Date:  2020-12-14       Impact factor: 3.310

6.  Effect of Age, Season, Body Condition, and Endocrine Status on Serum Free Cortisol Fraction and Insulin Concentration in Horses.

Authors:  K A Hart; D M Wochele; N A Norton; D McFarlane; A A Wooldridge; N Frank
Journal:  J Vet Intern Med       Date:  2016-02-09       Impact factor: 3.333

7.  In Obesity, HPA Axis Activity Does Not Increase with BMI, but Declines with Aging: A Meta-Analysis of Clinical Studies.

Authors:  Judit Tenk; Péter Mátrai; Péter Hegyi; Ildikó Rostás; András Garami; Imre Szabó; Margit Solymár; Erika Pétervári; József Czimmer; Katalin Márta; Alexandra Mikó; Nóra Füredi; Andrea Párniczky; Csaba Zsiborás; Márta Balaskó
Journal:  PLoS One       Date:  2016-11-21       Impact factor: 3.240

8.  Estrogen Deficiency Promotes Hepatic Steatosis via a Glucocorticoid Receptor-Dependent Mechanism in Mice.

Authors:  Matthew A Quinn; Xiaojiang Xu; Melania Ronfani; John A Cidlowski
Journal:  Cell Rep       Date:  2018-03-06       Impact factor: 9.423

Review 9.  The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor.

Authors:  Rene Baudrand; Anand Vaidya
Journal:  Int J Mol Sci       Date:  2018-02-11       Impact factor: 5.923

10.  Corticosteroid pharmacokinetic abnormalities in overweight and obese corticosteroid resistant asthmatics.

Authors:  Elena Goleva; Ronina Covar; Richard J Martin; Donald Y M Leung
Journal:  J Allergy Clin Immunol Pract       Date:  2016-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.